Table III.

AEs Occurring in ≥20% of all patients and selected AEs of interest.

AEs, n (%)	Tanespimycin dose, mg/m2
	150 n = 4	220 n = 9	275 n = 3	340 n = 7	420 n = 3	525 n = 3	All dose cohorts N = 29
Any	4 (100)	9 (100)	3 (100)	7 (100)	3 (100)	3 (100)	29 (100)
Non-haematological*
Diarrhoea	2 (50)	3 (33)	3 (100)	4 (57)	3 (100)	2 (67)	17 (59)
Back pain	3 (75)	1 (11)	2 (67)	2 (29)	2 (67)	0	10 (35)
Fatigue	1 (25)	2 (22)	2 (67)	2 (29)	2 (67)	2 (67)	11 (38)
Nausea	1 (25)	1 (11)	1 (33)	2 (29)	3 (100)	2 (67)	10 (35)
AST increased	1 (25)	1 (11)	1 (33)	2 (29)	2 (67)	2 (67)	9 (31)
Muscle spasms	1 (25)	3 (33)	0	3 (43)	1 (33)	0	8 (28)
ALT increased	1 (25)	1 (11)	0	2 (29)	2 (67)	1 (33)	7 (24)
Constipation	2 (50)	1 (11)	0	2 (29)	1 (33)	0	6 (21)
Dyspnea	0	1 (11)	0	4 (57)	0	1 (33)	6 (21)
Pain in extremity	2 (50)	3 (33)	0	0	1 (33)	0	6 (21)
Neuropathy	0	0	0	1 (14)	0	0	0
Haematological
Anaemia	1 (25)	3 (33)	1 (33)	1 (14)	1 (33)	0	7 (24)
Thrombocytopenia	1 (25)	1 (11)	0	3 (43)	1 (33)	0	6 (21)
Neutropenia	0	0	0	0	0	0	0

AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

^*AEs affecting at least 20% of the total group.